1. Gandhi TK, Singh H (2020) Reducing the risk of diagnos‐
tic error in the COVID-19 era. J Hosp Med 15: 363–366.
2. Stelfox HT, Bates DW, Redelmeier DA (2003) Safety of
patients isolated for infection control. JAMA 290: 1899–
1905.
3. Bancos I, Prete A (2021) Approach to the patient with
adrenal incidentaloma. J Clin Endocrinol Metab 106:
3331–3353.
4. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT
(1983) Occurrence of pheochromocytoma in Rochester,
Minnesota, 1950 through 1979. Mayo Clin Proc 58: 802–
804.
5. Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker
EJ, et al. (2013) Pheochromocytoma crisis is not a surgi‐
cal emergency. J Clin Endocrinol Metab 98: 581–591.
6. Whitelaw BC, Prague JK, Mustafa OG, Schulte KM,
Hopkins PA, et al. (2014) Phaeochromocytoma crisis. Clin
Endocrinol (Oxf) 80: 13–22.
7. Guerrero MA, Schreinemakers JMJ, Vriens MR, Suh I,
Hwang J, et al. (2009) Clinical spectrum of pheochromo‐
cytoma. J Am Coll Surg 209: 727–732.
8. Lenders JWM, Eisenhofer G, Mannelli M, Pacak K (2005)
Phaeochromocytoma. Lancet 366: 665–675.
9. Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger
WM, et al. (2007) Adverse drug reactions in patients with
phaeochromocytoma: incidence, prevention and manage‐
ment. Drug Saf 30: 1031–1062.
10. Rosas AL, Kasperlik-Zaluska AA, Papierska L, Bass BL,
Pacak K, et al. (2008) Pheochromocytoma crisis induced
by glucocorticoids: a report of four cases and review of
the literature. Eur J Endocrinol 158: 423–429.
11. Rebollo-Román A, Alhambra-Expósito MR, Herrera-
12.
13.
14.
15.
16.
17.
18.
19.
Martínez Y, Leiva-Cepas F, Alzas C, et al. (2021) Cate‐
cholaminergic crisis after a bleeding complication of
COVID-19 Infection: a case report. Front Endocrinol
(Lausanne) 12: 693004.
Naghshineh H, Hasanpour A, Ziaei N, Sadeghi M, Meftah
N (2022) Pheochromocytoma triggered by coronavirus
disease 2019: a case report. J Med Case Rep 16: 233.
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E,
Sergentanis TN, et al. (2020) Hematological findings and
complications of COVID-19. Am J Hematol 95: 834–847.
Oberbeck R (2006) Catecholamines: physiological immu‐
nomodulators during health and illness. Curr Med Chem
13: 1979–1989.
Wang JS, Cheng LJ (1999) Effect of strenuous, acute exer‐
cise on alpha2-adrenergic agonist-potentiated platelet acti‐
vation. Arterioscler Thromb Vasc Biol 19: 1559–1565.
Ziegler MG, Bao X, Kennedy BP, Joyner A, Enns R
(2002) Location, development, control, and function of
extraadrenal phenylethanolamine N-methyltransferase.
Ann N Y Acad Sci 971: 76–82.
Barrett C, van Uum SHM, Lenders JWM (2015) Risk of
catecholaminergic crisis following glucocorticoid admin‐
istration in patients with an adrenal mass: a literature
review. Clin Endocrinol (Oxf) 83: 622–628.
Mazza A, Armigliato M, Marzola MC, Schiavon L,
Montemurro D, et al. (2014) Anti-hypertensive treatment
in pheochromocytoma and paraganglioma: current man‐
agement and therapeutic features. Endocrine 45: 469–478.
Douma S, Petidis K, Doumas M, Papaefthimiou P,
Triantafyllou A, et al. (2008) Prevalence of primary
hyperaldosteronism in resistant hypertension: a retrospec‐
tive observational study. Lancet 371: 1921–1926.
Pheochromocytoma during COVID-19
20. Mao JJ, Baker JE, Rainey WE, Young WF Jr, Bancos I
(2021) Concomitant pheochromocytoma and primary
aldosteronism: a case series and literature review. J
Endocr Soc 5: bvab107.
21. Yamada T, Fukuoka H, Hosokawa Y, Odake Y, Yoshida
K, et al. (2020) Patients with pheochromocytoma exhibit
low aldosterone renin ratio-preliminary reports. BMC
Endocr Disord 20: 140.
22. Sakamoto N, Tojo K, Saito T, Fujimoto K, Isaka T, et al.
(2009) Coexistence of aldosterone-producing adrenocorti‐
cal adenoma and pheochromocytoma in an ipsilateral
adrenal gland. Endocr J 56: 213–219.
23. Gubbi S, Nazari MA, Taieb D, Klubo-Gwiezdzinska J,
Pacak K (2020) Catecholamine physiology and its impli‐
cations in patients with COVID-19. Lancet Diabetes
Endocrinol 8: 978–986.
24. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall
RS, et al. (2020) COVID-19: consider cytokine storm syn‐
dromes and immunosuppression. Lancet 395: 1033–1034.
265
25. Chen G, Wu D, Guo W, Cao Y, Huang D, et al. (2020)
Clinical and immunological features of severe and moder‐
ate coronavirus disease 2019. J Clin Invest 130: 2620–
2629.
26. Zhou F, Yu T, Du R, Fan G, Liu Y, et al. (2020) Clinical
course and risk factors for mortality of adult inpatients
with COVID-19 in Wuhan, China: a retrospective cohort
study. Lancet 395: 1054–1062.
27. Rhen T, Cidlowski JA (2005) Antiinflammatory action of
glucocorticoids—new mechanisms for old drugs. N Engl J
Med 353: 1711–1723.
28. Konig MF, Powell M, Staedtke V, Bai RY, Thomas DL, et
al. (2020) Preventing cytokine storm syndrome in
COVID-19 using α-1 adrenergic receptor antagonists. J
Clin Invest 130: 3345–3347.
29. Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, et al.
(2018) Disruption of a self-amplifying catecholamine loop
reduces cytokine release syndrome. Nature 564: 273–277.
...
論文の公開元へ
